The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Effect of Sustained Smoking Cessation Counseling and Provision of Medication vs Shorter-term Counseling and Medication Advice on Smoking Abstinence in Patients Recently Diagnosed With Cancer: A Randomized Clinical Trial
Open accessAbstract
Importance: Persistent smoking may cause adverse outcomes among patients with cancer. Many cancer centers have not fully implemented evidence-based tobacco treatment into routine care. Objective: To determine the effectiveness of sustained telephone counseling and medication (intensive treatment) compared with shorter-term telephone counseling and medication advice (standard treatment) to assist patients recently diagnosed with cancer to quit smoking. Design, Setting, and Participants: This unblinded randomized clinical trial was conducted at Massachusetts General Hospital/Dana-Farber/Harvard Cancer Center and Memorial Sloan Kettering Cancer Center. Adults who had smoked 1 cigarette or more within 30 days, spoke English or Spanish, and had recently diagnosed breast, gastrointestinal, genitourinary, gynecological, head and neck, lung, lymphoma, or melanoma cancers were eligible. Enrollment occurred between November 2013 and July 2017; assessments were completed by the end of February 2018. Interventions: Participants randomized to the intensive treatment (n = 153) and the standard treatment (n = 150) received 4 weekly telephone counseling sessions and medication advice. The intensive treatment group also received 4 biweekly and 3 monthly telephone counseling sessions and choice of Food and Drug Administration-approved cessation medication (nicotine replacement therapy, bupropion, or varenicline). Main Outcome and Measures: The primary outcome was biochemically confirmed 7-day point prevalence tobacco abstinence at 6-month follow-up. Secondary outcomes were treatment utilization rates. Results: Among 303 patients who were randomized (mean age, 58.3 years; 170 women [56.1%]), 221 (78.1%) completed the trial. Six-month biochemically confirmed quit rates were 34.5% (n = 51 in the intensive treatment group) vs 21.5% (n = 29 in the standard treatment group) (difference, 13.0% [95% CI, 3.0%-23.3%]; odds ratio, 1.92 [95% CI, 1.13-3.27]; P < .02). The median number of counseling sessions completed was 8 (interquartile range, 4-11) in the intensive treatment group. A total of 97 intensive treatment participants (77.0%) vs 68 standard treatment participants (59.1%) reported cessation medication use (difference, 17.9% [95% CI, 6.3%-29.5%]; odds ratio, 2.31 [95% CI, 1.32-4.04]; P = .003). The most common adverse events in the intensive treatment and standard treatment groups, respectively, were nausea (n = 13 and n = 6), rash (n = 4 and n = 1), hiccups (n = 4 and n = 1), mouth irritation (n = 4 and n = 0), difficulty sleeping (n = 3 and n = 2), and vivid dreams (n = 3 and n = 2). Conclusions and Relevance: Among smokers recently diagnosed with cancer in 2 National Cancer Institute-designated Comprehensive Cancer Centers, sustained counseling and provision of free cessation medication compared with 4-week counseling and medication advice resulted in higher 6-month biochemically confirmed quit rates. However, the generalizability of the study findings is uncertain and requires further research. Trial Registration: ClinicalTrials.gov Identifier: NCT01871506.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910
The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research
Buysse, D. J., Reynolds, C. F., Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989) · Psychiatry Research · doi:10.1016/0165-1781(89)90047-4 · Cited by 35,234
A Brief Measure for Assessing Generalized Anxiety Disorder: The GAD-7
Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Löwe, B. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.10.1092 · Cited by 31,765
Health Behavior and Health Education: Theory, Research, and Practice
(1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-4-350_1 · Cited by 13,232
Analysis of Incomplete Multivariate Data
Booth, D. E., & Schafer, J. L. (2000) · Technometrics · doi:10.2307/1271466 · Cited by 5,627
The Health consequences of smoking—50 years of progress : a report of the Surgeon General
Lushniak, B. D., Samet, J. M., Pechacek, T. F., Norman, L., & Taylor, P. A. (2014) · Cited by 4,990
Treating tobacco use and dependence-Clinical practice guideline
Mc, F. (2000) · Medical Entomology and Zoology · Cited by 3,616
Physician advice for smoking cessation
Stead, L. F., Buitrago, D., Preciado, N., Sanchez, G., Hartmann-Boyce, J., & Lancaster, T. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000165.pub4 · Cited by 1,955
Cancer Research Communications
Calura, E., Fruscio, R., Paracchini, L., Bignotti, E., Martini, P., Sales, G., Beltrame, L., Clivio, L., Ceppi, L., Di Marino, M., et al. (2021) · doi:10.1158/1078-0432 · Cited by 1,537
American Society of Clinical Oncology
Pochon, S. (2005) · American Journal of Cancer · doi:10.2165/00024669-200504040-00008 · Cited by 1,429
Research works printed but not linked: 1
- National Center for Chronic Disease Prevention and Health Promotion Office on Smoking and Health, 2020, Smoking Cessation: A Report of the Surgeon General
Cited by
Sorted by citations
Smoking Cessation, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Shields, P. G., Bierut, L. J., Arenberg, D. A., Balis, D. S., Cinciripini, P. M., Davis, J. M., Edmondson, D. M., Feliciano, J., Hitsman, B. L., Hudmon, K. S., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0013 · Cited by 83
Self-citationSurvival Outcomes of an Early Intervention Smoking Cessation Treatment After a Cancer Diagnosis
Cinciripini, P. M., Kypriotakis, G., Blalock, J. A., Karam‐Hage, M., Beneventi, D., Robinson, J. D., Minnix, J. A., & Warren, G. W. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.4890 · Cited by 64
Thrul, J., Howe, C. L., Devkota, J., Alexander, A. C., Allen, A. M., Businelle, M. S., Hébert, E. T., Heffner, J. L., Kendzor, D. E., Ra, C. K., et al. (2022) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntac271 · Cited by 36
Webb, J., Peerbux, S., Ang, A., Siddiqui, S., Sherwani, Y., Ahmed, M., MacRae, H., Puri, H., Majeed, A., & Glasner, S. V. (2022) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntac113 · Cited by 31
“7 The following content areas were included: (1) motivation, (2) dependence and withdrawal, (3) social support, (4) identifying triggers, (5) coping with cravings, (6) cognitive restructuring, (7) managing negative affect, (8) weight gain, and (9) relapse prevention planning.”
BackgroundWarner, E. T., Park, E. R., Luberto, C. M., Rabin, J. T., Perez, G. K., & Ostroff, J. S. (2021) · Psycho-Oncology · doi:10.1002/pon.5859 · Cited by 31
“screen, 405 were ineligible, 143 declined, and 303 were randomized.(13) Participants were randomized 1:1 to receive intensive treatment or standard treatment both of which involved a motivational interviewing approach to smoking cessation but differed in terms of the number of sessions.”
BackgroundMethodSelf-citation
Metadata
- Authors
- Park, E. R., Perez, G. K., Regan, S., Muzikansky, A., Levy, D. E., Temel, J. S., Rigotti, N. A., Pirl, W. F., Irwin, K. E., Partridge, A. H., Cooley, M. E., Friedman, E. R., Rabin, J., Ponzani, C., Hyland, K. A., Holland, S., Borderud, S., Sprunck, K., Kwon, D., Peterson, L., Miller-Sobel, J., Gonzalez, I., Whitlock, C. W., Malloy, L., de León-Sanchez, S., O’Brien, M., & Ostroff, J. S.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- Moffitt Cancer Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- Dana-Farber Cancer Institute (US)
- Department of Psychiatry & Behavioral Sciences, Tobacco Treatment Program, Memorial Sloan Kettering Cancer Center, New York, New York
- Corresponding author
- Park, Elyse R.
- ORCID
- Park, Elyse R.
- Perez, Giselle K.
- Regan, Susan
- Muzikansky, Alona
- Levy, Douglas E.
- Temel, Jennifer S.
- Rigotti, Nancy A.
- Pirl, William F.
- Irwin, Kelly E.
- Partridge, Ann H.
- Cooley, Mary E.
- Friedman, Emily R.
- Rabin, Julia
- Hyland, Kelly A.
- Holland, Susan
- Borderud, Sarah
- Kwon, Diana
- Gonzalez, Irina
- Malloy, Laura
- Ostroff, Jamie S.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2020-10-13
- Volume
- 324
- Issue
- 14
- Pages
- 1406
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC8094414
- OpenAlex
- W3092359548
- Cited by
- 114
- References
- 40
- Citations by year
- 2026: 17 · 2025: 18 · 2024: 17 · 2023: 18 · 2022: 31 · 2021: 11 · 2020: 2
- FWCI
- 9.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- National Institutes of Health (UL1TR002384)
- National Cancer Institute (K24CA197382, R01CA166147, K08CA230185, P30CA008748)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- smoking cessation, cancer patients, telephone counseling, nicotine replacement therapy, bupropion, varenicline, smoking abstinence, treatment utilization, Spanish-speaking patients, breast cancer, lung cancer, head and neck cancer, gastrointestinal cancer, lymphoma, melanoma, genitourinary cancer, gynecologic cancer
- MeSH terms
- Varenicline, Smoking Cessation Agents, Aged, Cotinine, Counseling, Decision Support Techniques, Female, Humans, Male, Middle Aged, Neoplasms, Saliva, Smoking, Telephone, Temperance, Smoking Cessation, Bupropion, Patient Satisfaction, Patient Selection, Tobacco Use Cessation Devices, Motivational Interviewing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
